Screener
Integra LifeSciences IART Specialty Surgery — Total Revenues
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Integra LifeSciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000917520-26-000058
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Neurosurgery | $213,264 | $208,992 | $411,458 | $399,904 |
| Surgical Instruments | 54,806 | 53,080 | 102,039 | 104,030 |
| ENT Solutions | 41,199 | 41,886 | 78,907 | 80,688 |
| Total Specialty Surgery | 309,269 | 303,958 | 592,404 | 584,622 |
| Wound Reconstruction Solutions | 81,305 | 84,747 | 160,952 | 159,526 |
| Private Label | 28,187 | 26,900 | 57,323 | 54,110 |
| Total Tissue Reconstruction | 109,492 | 111,647 | 218,275 | 213,636 |
| Total Revenue | $418,761 | $415,605 | $810,679 | $798,258 |
Item 1. Financial Statements
FAQ
- What is Integra LifeSciences's specialty surgery — total revenues?
- Integra LifeSciences (IART) reported specialty surgery — total revenues of $309.27M in Q2 2026.
- What does specialty surgery — total revenues mean?
- This metric represents the total gross revenue generated by the Specialty Surgery business segment from the sale of medical devices and related services. It serves as a primary indicator of the segment's market demand and top-line growth performance within the broader medical technology portfolio.
Ask your AI about Integra LifeSciences's specialty surgery — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude